Abstract:Heart failure (HF) is a globally prevalent cardiovascular disease, but effective drug targets and diagnostic models are still lacking. This study was designed to investigate effective drug targets and diagnostic models for HF in terms of miRNA targets, hoping to contribute to the understanding and treatment of HF. Using HF miRNA and gene expression profile data from the GEO database, we analyzed differentially expressed miRNAs/gene identification in HF using Limma and predicted miRNA targets by the online TargetScan database. Subsequently, gene set enrichment analysis and annotation were performed using WebGestaltR package. Protein-protein interactions were identified using the STRING database. The proximity of drugs to treat HF was also calculated and predicted for potential target therapeutic drug. In addition, further drug identification was performed by molecular docking. Finally, diagnostic models were constructed based on differential miRNAs. The GEO dataset was used to screen 66 differentially expressed miRNAs, incorporating 56 downregulated miRNAs and 10 upregulated miRNAs. The JAK-STAT signaling pathway, MAPK signaling pathway, p53 signaling pathway, Prolactin signaling pathway, and TGF-beta signaling pathway were enriched, as shown by KEGG enrichment analysis on the target genes. In addition, we found that 83 genes were upregulated and 92 genes were downregulated in HF patients vs. healthy individuals. Based on the inflammation-related score, hypoxia-related score, and energy metabolism-related score, we identified key miRNA-mRNA pairs and constructed an interaction network. Following that, TAP1, which had the highest expression and network connectivity in acute HF with crystal and molecular docking studies, was selected as a key candidate gene in the network. And the compound DB04847 was selected to produce a large number of favorable interactions with TAP1 protein. Finally, we constructed two diagnostic models based on the differential miRNAs hsa-miR-6785-5p and hsa-miR-4443. In conclusion, we identified TAP1, a key candidate gene in the diagnosis and treatment of HF, and determined that compound DB04847 is highly likely to be a potential inhibitor of TAP1. The TAP1 gene was also found to be regulated by hsa-miR-6785-5p and hsa-miR-4443, and a diagnostic model was constructed. This provides a new promising direction to improve the diagnosis, prognosis, and treatment outcome and guide more effective immunotherapy strategies of HF.

The potential of herbal drugs to treat heart failure: The roles of Sirt1/AMPK

Natural Products from Traditional Chinese Medicine for the Prevention and Treatment of Heart Failure: Progress and Perspectives.

Discovery of Herbacetin As a Novel SGK1 Inhibitor to Alleviate Myocardial Hypertrophy

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

Energy metabolism and redox balance: How phytochemicals influence heart failure treatment

Tanshinone IIA Protects Against Heart Failure Post-Myocardial Infarction Via AMPKs/mTOR-dependent Autophagy Pathway.

The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms

Progress on the role of traditional Chinese medicine in therapeutic angiogenesis of heart failure

Resveratrol, an Activator of SIRT1, Upregulates AMPK and Improves Cardiac Function in Heart Failure

Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Mining Potential Drug Targets and Constructing Diagnostic Models for Heart Failure Based on Mirna-Mrna Networks

Energy metabolism disorders and potential therapeutic drugs in heart failure

Protective Effect of Natural Medicinal Plants on Cardiomyocyte Injury in Heart Failure: Targeting the Dysregulation of Mitochondrial Homeostasis and Mitophagy

Sirt1 improves heart failure through modulating the NF-κB p65/microRNA-155/BNDF signaling cascade

Modulatory Effects of Chinese Herbal Medicines on Energy Metabolism in Ischemic Heart Diseases

Traditional Chinese Medicine Targeting Heat Shock Proteins as Therapeutic Strategy for Heart Failure

Integrated Network Pharmacology and Metabolomics to Reveal the Mechanism of QiShenYiQi Dripping Pills Against Cardiac Structural and Functional Abnormalities

Fatty acid metabolism disorders and potential therapeutic traditional Chinese medicines in cardiovascular diseases

A simplified herbal formula for the treatment of heart failure: Efficacy, bioactive ingredients, and mechanisms

Traditional Chinese medicine and mitophagy: A novel approach for cardiovascular disease management

Potential Cardiovascular Disease Treatment by Natural Drugs Targeting the HIF-1α Factor and its Pathway